|
|||||||||
|
|||||||||
|
March 2009 - Celtic Catalysts opens UK process facility Speaking about its newly opened UK facility, Celtic Catalysts chief executive Brian Kelly said: “This is another significant milestone in the development and expansion of Celtic Catalysts. Our new production capabilities enable us to supply sizeable quantities of our own proprietary products and also means that we can now work with our contract R&D partners from milligram to tens of kilogram scale.” Celtic Catalysts is a leading supplier of difficult to make chiral and non-chiral products to the Fine Chemical, Pharmaceutical and Biotech industries. Celtic Catalysts has developed a comprehensive portfolio of intellectual property and carved out uniquely strong niches for itself in the areas of asymmetric catalysis, phosphorus chemistry and process development. |
![]() Inside a large reactor at the Wilton site |
||
October 2008 - Celtic Catalysts secures €500,000 investment |
|||
May 2008 - Celtic Catalysts scoops NovaUCD 2008 Innovation Award “Celtic Catalysts is a really exciting spin-out company established to commercialise the output of UCD research,” said Dr Hugh Brady, President of UCD, who presented the award. “The generation of new high-tech ventures, such as Celtic Catalysts, is seen as one increasingly important measure of the impact of our research output on economic development in Ireland.” Since 2004, Celtic Catalysts has secured €2 millionin investment from 4th Level Ventures, Enterprise Ireland, Údarás na Gaeltachta and the Business Expansion Scheme (BES). In addition it has secured two European Commission grants under the prestigious Marie Curie funding scheme. The company currently employs 17 people and is headquartered in NovaUCD the Innovation and Technology Transfer Centre at UCD. In addition to product sales, Celtic Catalysts has already signed several research alliance agreements with a number of multinational pharmaceutical companies. These research alliance agreements enable Celtic Catalysts utilise their expertise and technology to solve problems being encountered by pharmaceutical and biotech companies in the manufacture of their drugs. Celtic Catalysts is currently in fundraising mode and plans to expand its workforce to over 30 people, mostly at PhD level, within the next two years, to occupy its own laboratory facilities to manufacture bulk quantities of its products in addition to securing alliances and to supply agreements with all major Pharma and fine chemical companies. The NovaUCD Innovation Award was established in 2004 to highlight UCD’s commitment to innovation. The Award is presented annually to an individual, company or organisation in recognition of excellence in innovation or of success achieved in the commercialisation of UCD research or other intellectual activity. The previous award winners are Professor Ciaran Regan (2007), Professor Conor Heneghan (2006), Professor Barry Smyth (2005) and Professor Mark Rogers (2004). Celtic Catalysts is a leading supplier of chiral products and technology to the Fine Chemical, Pharmaceutical and Biotech industries. Celtic Catalysts focuses on the area of chiral synthesis and it has developed a comprehensive portfolio of intellectual property and carved out a uniquely strong niche for itself in the specialised area of P-chiral technology. The company is commercialising chiral technology, developed over many years in UCD’s School of Chemistry and Chemical Biology. |
|||
Febuary 2008 - Celtic Catalysts wins "rising star award" at international biotech competition Dr Brian Kelly and Professor Declan Gilheany co-founded Celtic Catalysts in 2000 as a spin-out from UCD’s School of Chemistry and Chemical Biology. Celtic Catalysts currently employs a staff of 17 and is headquartered in NovaUCD, the Innovation and Technology Transfer Centre at UCD. |
|||
| January 2008 - Celtic Catalysts Appoints New CEO |
| © Copyright 2009 by Celtic Catalysts. All rights reserved. |

